key: cord-0689159-nqkpuqb9
authors: McShane, Cathy; Kiat, Clifford; Rigby, Jonathan; Crosbie, Órla
title: The mRNA COVID-19 vaccine – a rare trigger of Autoimmune Hepatitis?
date: 2021-07-08
journal: J Hepatol
DOI: 10.1016/j.jhep.2021.06.044
sha: bda549d6dfb9aacc3a94e09280f457f1a442258f
doc_id: 689159
cord_uid: nqkpuqb9

nan

We read with interest the letters "Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) Vaccine: Causality or casualty?" by Bril et al. 1 and "Autoimmune hepatitis following sars-cov-2 VACCINE: MAY not be a casualty" by Rocco et al 2 which highlight the hypothesis that COVID-19 mRNA-based vaccines might increase the risk of developing autoimmune diseases. There are growing reports of autoimmune diseases developing after Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, including Guillain-Barré syndrome and Primary Biliary Cholangitis 3 . It is speculated that SARS-CoV-2 can disturb selftolerance and trigger autoimmune responses through cross-reactivity with host cells and that the COVID-19 mRNA vaccines may trigger the same response 4, 5 .

We report a further case of Autoimmune Hepatitis (AIH) following COVID-19 mRNA vaccination.

Our patient is a 71 year old Caucasian female. Background history was significant for cholecystectomy 20 years previously, left total hip replacement and osteoarthritis of the knees. There were no risk factors for autoimmune disease. She was on no regular medications or supplements.

She received the Moderna mRNA vaccine on the 16 th of April 2021. During the 24hour period around vaccination she took 2g of paracetamol. Four days post vaccination she noticed jaundice. She attended her primary carer on the 26 th of April (+10 days post vaccination). Laboratory results were markedly abnormal (Bilirubin 270umol/L, Alkaline Phosphatase 217U/L, ALT 1067U/L). She was promptly referred to our hepatology services.

On physical examination she was jaundiced. Laboratory results were negative for hepatitis B, C, and E, Epstein-Barr virus, cytomegalovirus and HIV. Hepatitis A IgG was positive with a negative IgM. Smooth muscle antibody was strongly positive with a titre of 2560 and an anti-actin pattern. Total IgG was markedly raised at 21.77g/L. Liver ultrasound, magnetic resonance cholangiopancreatography and computer tomography pancreas protocol showed distal common bile duct dilation of 1.4cm consistent with prior cholecystectomy.

On receipt of positive autoantibodies and a rising liver profile (Bilirubin 332umol/L, ALT 1143U/L, AST 1469U/L, Alkaline Phosphatase 237U/L and INR 1.4), steroids were commenced on the 4 th of May and liver biopsy was performed the following day. Up to 20 portal tracts were present, each expanded with a marked polymorphous inflammatory cell infiltrate of plasma cells, lymphocytes, eosinophils, neutrophils and PASD positive ceroid laden macrophages; interface hepatitis was present and continuous in most tracts, with portal-portal and portal-central bridging necrosis ( Figure 1A to C). The findings were compatible with AIH, however drugs, toxins or infections could not be ruled out as aetiological agents.

Since discharge from hospital our patient remains well and liver biochemistry has continued to improve on a tapering course of Prednisolone ( Figure 1D ).

There are a number of similarities between the previously described cases and our own. Firstly there was a short interval between vaccination and symptom onset in all cases. Capecchi et al 6 in response to the first case questioned whether this was too short an interval to develop the necessary immune activation. It is indeed short when compared to established causatives agents of drug induced autoimmune liver disease such as immune checkpoint inhibitors where a latency period of 2 to 24 weeks has been described 7 . However a much shorter latency period is described for other vaccine-induced autoimmune conditions such as Guillain-Barré syndrome (median onset 13 days) 8 .

Secondly histological appearances are similar between our case and that described by Bril et al. Both cases had an eosinophil infiltration which is more typical of a drug induced liver injury. This raises the possibility that this is a vaccine-related druginduced liver injury with features of AIH rather than the vaccine causing immune dysregulation.

Unlike the other cases, our patient had no confounding risk factors for developing autoimmune liver disease such as other autoimmune conditions or recent pregnancy and she received a different mRNA vaccine, Moderna rather than Pfizer-BioNTech.

These findings raise the question as to whether COVID-19 mRNA vaccination can, through activation of the innate immune system and subsequent non-specific activation of autoreactive lymphocytes, lead to the development of autoimmune diseases including AIH or trigger a drug-induced liver injury with features of AIH. The trigger, if any, may become more apparent over time, especially following withdrawal of immunosuppression. As with other autoimmune diseases associated with vaccines the causality or casualty factor will prove difficult to tease apart and should not distract from the overwhelming benefits of mass COVID-19 vaccination. But it does beg the question whether or not these individuals should receive the second dose of a mRNA COVID-19 vaccine.

J o u r n a l P r e -p r o o f 1A Marked portal tract (star) inflammation with enlargement and an irregular disrupted interface and a lobular hepatitis (long arrow)(100x). 1B At higher magnification the portal tract inflammation is mononuclear with spill over and damage to the periportal hepatocytes (200x). 1C At high magnification many of the mononuclear inflammatory cells are plasma cells (short arrows). This lymphoplasmacytic infiltrate damages periportal hepatocytes with some forming rosettes (long arrow) and with occasional emperipolesis of lymphocytes (arrowhead)(400x). 1D Trend of ALT, AST and Bilirubin following introduction of steroids.

Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) Vaccine: Causality or casualty?

Autoimmune hepatitis following sars-cov-2 VACCINE: MAY not be a casualty

Primary biliary cholangitis associated with SARS-CoV-2 infection

COVID-19 and autoimmune diseases

SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis

Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) Vaccine: Causality or casualty?

Best practices for detection, assessment and management of suspected immunemediated liver injury caused by immune checkpoint inhibitors during drug development

Guillain-Barré Syndrome Following Influenza Vaccination